Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer (ICE)

This study has been completed.
Odense University Hospital
Aalborg Universitetshospital
Information provided by (Responsible Party):
Benny Vittrup Jensen, Herlev Hospital Identifier:
First received: June 27, 2011
Last updated: March 18, 2012
Last verified: March 2012
This is an open, multicenter phase II trial of therapy with a combination of cetuximab, and irinotecan every second week combined with a daily dose of everolimus to patients with metastatic colorectal cancer with Kirsten rat sarcoma viral oncogene (KRAS) mutation or to patients resistent to cetuximab and irinotecan therapy for metastatic colorectal cancer.

Condition Intervention Phase
Metastatic Colorectal Cancer
Drug: Everolimus
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Examination of Irinotecan, Cetuximab and Everolimus to Chemotherapy Resistent Patients With Metastatic Colorectal Cancer and KRAS Mutations or After Progression With KRAS Wildtype on Irinotecan and Cetuximab - Effect and Biological Markers

Resource links provided by NLM:

Further study details as provided by Herlev Hospital:

Primary Outcome Measures:
  • Clinical benefit (SD+PR+CR) [ Time Frame: 1 year ]
    Clinical benefit is defined as the number of patients with stable disease lasting 2 months and partial response and CR as defined in RECIST 1.1

Enrollment: 100
Study Start Date: January 2010
Study Completion Date: March 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cetuximab, everolimus, irinotecan Drug: Everolimus

Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.

Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan.

Drug: Everolimus
1.66 mg per day up to 7½ mg per day
Active Comparator: Cetuximab, everolimus and Irinotecan.

Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.

Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus.

Drug: Everolimus
1.66 mg per day up to 7½ mg per day

Detailed Description:

Main objective:

  • Number of patients with progressive disease that obtain disease control defined as the sum of patients that obtain a Complete Remission (CR), Partial Remission(PR, or stable disease (SD))

Secondary objectives:

  • Time to progression after first therapy.
  • Length of disease control (CR, PR and SD)
  • Survival from date of start of therapy.
  • Safety and toxicity of the therapy graded according to Common Toxicity Criteria version 3.0
  • Influence of smoking on disease control, response, survival and time to progression and other effect parameters in the investigation.
  • Significance of metabolic response evaluated by a Photon Emissions Tomography (PET)/Computer Tomography(CT)scan.
  • Blood: Examine the influence of potential predictive and prognostic tumour biomarkers in blood as lactate dehydrogenase (LDH), Carcinoembryonic antigen (CEA), Vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), Human Epidermal growth factor Receptor 2 (HER-2), YKL-40, Interleukin-6 (IL-6) ,metallopeptidase inhibitor 1 (TIMP-1), procollagen type I N-terminal propeptide (PINP), Procollagen type 3 N-terminal propeptide (P3NP), gen-, micro-ribonucleinate (microRNA)- and protein array profiles, metabolomics and C-reactive protein (CRP) 2 weeks after start of therapy and thereafter every 8.weeks on disease control, response, survival and time to progression and other parameters investigated.
  • Tissue: Examine possible predictive and prognostic biomarkers in tissue from primary tumour or metastases for micro-RNAarray profiles, mutations in K-RAS, murine sarcoma viral oncogene homolog (BRAF), Phosphoinositide 3-kinase (PIK3CA), EGFR, tumor protein 53 (p53), and protein expression and polymorphisms of th phosphatase and tensin homolog (PTEN), epiregulin (EREG), amphiregulin (AREG), Insulin-like growth factor 1 (IGF-1), IGF-1 Receptor (IGF-1R), VEGF, p53, topoisomerase 1 (Topo1), YKL-40, and TIMP-1
  • Correlation between possible predictive and prognostic biomarkers in blood and tissue.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Criteria for inclusion:

  • Patients with a histological or cytological verified adenocarcinoma of the colon or rectum with non-resectable or metastatic cancer.
  • Patients with measurable disease without previous radiotherapy
  • Patients with metastatic colorectal cancer with progression after previous therapy with 5-fluoropyrimidines, oxaliplatin or irinotecan. Patients should have been treated with oxaliplatin, but if oxaliplatin has be contraindicated or not tolerated the patient can participate in the trial.
  • Patients with KRAS-mutation in their primary tumour or metastasis.
  • Patients with progression after therapy with irinotecan or cetuximab independent of KRAS mutation status.
  • Previous radiotherapy is allowed to less than 25 % of the bone marrow.
  • Age more or equal to 18 years.
  • Performance status less than 3.
  • An expected survival time of at least 3 months.
  • Signed informed consent according to specifications from the ethical comites.

Criteria for exclusion:

  • Former or other concurrent malignant disease except treated basal cell carcinoma or in situ cervical cancer.
  • No cytotoxic therapy or other experimental treatment within 28 days before inclusion.
  • No former therapy with everolimus or other rapamycin as sirolimus or temsirolimus.
  • No known hypersensitivity for one or more components in the therapy.
  • No uncontrolled diabetes
  • No serious non-healing wounds, gastric ulcers, bone fractures, greater surgical procedures, major traumatic injuries within 28 days before inclusion.
  • No ongoing bleeding or pathological condition associated with a risk of bleeding.
  • No liver disease as cirrhose, chronical active hepatitis or chronic persistent hepatitis.
  • No gastrointestinal disturbances in function that might cause a major change in the absorption of everolimus as ulcerative disease, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome.
  • No planned immunisation with attenuated virus in the study period.
  • Patients that is unable to follow treatment or evaluation plan.
  • Every condition or therapy that after the judgement of investigator might infer the patient a risk or influence the trials objective.
  • Pregnant or breastfeeding women.
  • At fertile women this is insured by a negative test of pregnancy or use of a safe anticonception during the trial period and at least 3 months after end of treatment.
  • Patients with active infections or other serious medical co-morbidity, that might prevent the patient from being treated with the protocoled therapy.
  • Incapacitated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01387880

Herlev University Hospital
Herlev, Copenhagen, Denmark, 2730
Sponsors and Collaborators
Herlev Hospital
Odense University Hospital
Aalborg Universitetshospital
Principal Investigator: Benny V Jensen, MD University of Copenhagen
  More Information

Responsible Party: Benny Vittrup Jensen, onsultant, Herlev Hospital Identifier: NCT01387880     History of Changes
Other Study ID Numbers: GI 0923 ICE
Study First Received: June 27, 2011
Last Updated: March 18, 2012

Keywords provided by Herlev Hospital:
Metastatic colorectal cancer
Third line therapy
Fourth line therapy
KRAS mutation status

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents processed this record on May 24, 2017